Controlling antibody delivery, mechanical properties, and cell response of alginate-chitosan polyelectrolyte complexes
Therapeutic antibodies have become attractive treatment options for numerous diseases, including various cancers, based on their ability to target and bind to specific proteins or antigens. The antiangiogenic antibody, bevacizumab, targets and binds to VEGF to prevent angiogenesis. Bevacizumab has been approved for the treatment of recurrent glioblastoma, with concurrent radiation and chemotherapy, however the clinical efficacy of bevacizumab is still debated. As a large molecule therapeutic, bevacizumab cannot readily cross the blood brain barrier (BBB) to reach the tumor site. A local, injectable ...
(For more, see "View full record.")